These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anti-SSA/Ro positivity and congenital heart block: obstetric and foetal outcome in a cohort of anti-SSA/Ro positive pregnant patients with and without autoimmune diseases. Fredi M; Argolini LM; Angeli F; Trespidi L; Ramoni V; Zatti S; Vojinovic T; Donzelli D; Gazzola FG; Xoxi B; Andreoli L; Lojacono A; Ferrazzi E; Montecucco C; Chighizola CB; Meroni PL; Franceschini F; Cimaz R; Caporali R; Tincani A; Gerosa M Clin Exp Rheumatol; 2023 Mar; 41(3):685-693. PubMed ID: 36377571 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Friedman DM; Llanos C; Izmirly PM; Brock B; Byron J; Copel J; Cummiskey K; Dooley MA; Foley J; Graves C; Hendershott C; Kates R; Komissarova EV; Miller M; Paré E; Phoon CK; Prosen T; Reisner D; Ruderman E; Samuels P; Yu JK; Kim MY; Buyon JP Arthritis Rheum; 2010 Apr; 62(4):1138-46. PubMed ID: 20391423 [TBL] [Abstract][Full Text] [Related]
5. Neonatal lupus: bedside to bench and back. Buyon JP Scand J Rheumatol; 1996; 25(5):271-6. PubMed ID: 8921918 [TBL] [Abstract][Full Text] [Related]
6. Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials. Gleicher N; Elkayam U Autoimmun Rev; 2013 Sep; 12(11):1039-45. PubMed ID: 23684701 [TBL] [Abstract][Full Text] [Related]
7. [Congenital heart block associated with maternal anti SSA/SSB antibodies :a report of four cases]. Ayed K; Gorgi Y; Sfar I; Khrouf M Pathol Biol (Paris); 2004 Apr; 52(3):138-47. PubMed ID: 15063933 [TBL] [Abstract][Full Text] [Related]
8. [Neonatal lupus syndrome: Literature review]. Morel N; Georgin-Lavialle S; Levesque K; Guettrot-Imbert G; Le Guern V; Le Bidois J; Bessières B; Brouzes C; Le Mercier D; Villain E; Maltret A; Costedoat-Chalumeau N Rev Med Interne; 2015 Mar; 36(3):159-66. PubMed ID: 25240481 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Izmirly PM; Kim MY; Llanos C; Le PU; Guerra MM; Askanase AD; Salmon JE; Buyon JP Ann Rheum Dis; 2010 Oct; 69(10):1827-30. PubMed ID: 20447951 [TBL] [Abstract][Full Text] [Related]
10. Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Routsias JG; Kyriakidis NC; Friedman DM; Llanos C; Clancy R; Moutsopoulos HM; Buyon J; Tzioufas AG Arthritis Rheum; 2011 Sep; 63(9):2783-9. PubMed ID: 21618202 [TBL] [Abstract][Full Text] [Related]
11. Factors influencing fetal cardiac conduction in anti-Ro/SSA-positive pregnancies. Sonesson SE; Hedlund M; Ambrosi A; Wahren-Herlenius M Rheumatology (Oxford); 2017 Oct; 56(10):1755-1762. PubMed ID: 28957562 [TBL] [Abstract][Full Text] [Related]
12. Anti-Ro52 antibody level is an important marker of fetal congenital heart block risk in anti-Ro/SSA antibody positive pregnancy. Miyasato-Isoda M; Waguri M; Yamada Y; Miyano A; Wada Y Mod Rheumatol; 2018 Jul; 28(4):690-696. PubMed ID: 28880700 [TBL] [Abstract][Full Text] [Related]
13. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Izmirly PM; Costedoat-Chalumeau N; Pisoni CN; Khamashta MA; Kim MY; Saxena A; Friedman D; Llanos C; Piette JC; Buyon JP Circulation; 2012 Jul; 126(1):76-82. PubMed ID: 22626746 [TBL] [Abstract][Full Text] [Related]
15. Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block. Tonello M; Hoxha A; Mattia E; Zambon A; Visentin S; Cerutti A; Ghirardello A; Milanesi O; Ruffatti A Clin Rheumatol; 2017 May; 36(5):1155-1160. PubMed ID: 28204891 [TBL] [Abstract][Full Text] [Related]
16. Subclass distribution of maternal and neonatal anti-Ro(SSA) and La(SSB) antibodies in congenital heart block. Tseng CE; Caldwell K; Feit S; Chan EK; Buyon JP J Rheumatol; 1996 May; 23(5):925-32. PubMed ID: 8724310 [TBL] [Abstract][Full Text] [Related]
17. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Saleeb S; Copel J; Friedman D; Buyon JP Arthritis Rheum; 1999 Nov; 42(11):2335-45. PubMed ID: 10555029 [TBL] [Abstract][Full Text] [Related]
18. No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. Friedman D; Lovig L; Halushka M; Clancy RM; Izmirly PM; Buyon JP Clin Exp Rheumatol; 2017; 35(5):857-859. PubMed ID: 28598777 [TBL] [Abstract][Full Text] [Related]
19. Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block. Ivanchenko M; Thorlacius GE; Hedlund M; Ottosson V; Meneghel L; Björkander S; Ossoinak A; Tingström J; Bremme K; Sverremark-Ekström E; Gemzell-Danielsson K; Sonesson SE; Chemin K; Wahren-Herlenius M Ann Rheum Dis; 2021 Feb; 80(2):194-202. PubMed ID: 33004330 [TBL] [Abstract][Full Text] [Related]
20. Congenital heart block related to maternal autoantibodies: descriptive analysis of a series of 18 cases from a single center. Doti PI; Escoda O; Cesar-Díaz S; Palasti S; Teixidó I; Sarquella-Brugada G; Gómez O; Martínez JM; Espinosa G Clin Rheumatol; 2016 Feb; 35(2):351-6. PubMed ID: 26791874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]